{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-24-000096","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.157687+00:00","generated_at":"2026-06-01T07:24:04.416024+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Summit: Ivonescimab beats pembrolizumab in Phase III HARMONi-2 for PD-L1+ NSCLC","bullets":["Ivonescimab met primary endpoint PFS with statistically significant and clinically meaningful superiority over pembrolizumab.","Benefit observed across subgroups: PD-L1 low/high, squamous/non-squamous, and high-risk patients.","First drug to show statistically significant superiority over pembrolizumab in a head-to-head Phase III NSCLC trial.","Full data set to be presented at upcoming major medical conference; conference call June 3 at 8am ET.","Summit plans to expand development of ivonescimab into other tumors beyond NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-24-000096","json":"https://secwatch.observer/filing/0001599298-24-000096.json","markdown":"https://secwatch.observer/filing/0001599298-24-000096.md","text":"https://secwatch.observer/filing/0001599298-24-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000096/0001599298-24-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000096/smmt-20240530.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:24:04.416024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}